Corbus Pharmaceuticals Holdings, Inc. is a clinical stage biopharmaceutical company focused on developing novel therapies for oncology and obesity. It operates in the biotechnology industry advancing a pipeline that includes an antibody drug conjugate targeting Nectin 4 and a peripherally restricted CB1 receptor inverse agonist for weight management.

The company has not yet generated product revenue because its candidates remain in clinical development. Its income to date comes from licensing agreements and financing activities such as the license from CSPC for CRB 701 covering the United States Canada the European Union the United Kingdom and Australia.

In oncology Corbus competes with companies developing Nectin 4 directed antibody drug conjugates such as Bicycle Therapeutics Mabwell and Pfizer with its approved Padcev. Additional competitors targeting similar solid tumor indications include Bicara Therapeutics Genmab Johnson Johnson and Pfizer. Corbus differentiates its antibody drug conjugate through site specific conjugation and a novel linker that yields a homogeneous drug to antibody ratio of two and a longer half life with lower free payload exposure which may reduce toxicity relative to existing agents. In the obesity arena Corbus faces competition from glucagon like peptide 1 agonists offered by Novo Nordisk Lilly AstraZeneca and from other oral agents such as Structure Therapeutics and Viking Therapeutics. Its CB1 inverse agonist CRB 913 is designed to act peripherally to limit central nervous system side effects and gastrointestinal intolerance which may provide an advantage over existing therapies.

The company’s potential customers include patients with solid tumors such as cervical cancer head and neck squamous cell carcinoma and urothelial carcinoma as well as individuals seeking treatment for obesity. Healthcare providers hospitals clinics and payers would be the channels through which its therapies would be delivered upon regulatory approval.